Evidence map›Paper›PMID 26383970›Full record

ArticleCirculation research2015

GDF11 does not rescue aging-related pathological hypertrophy.

Shavonn C Smith, Xiaoxiao Zhang, Xiaoying Zhang, Polina Gross, Timothy Starosta, Sadia Mohsin, Michael Franti, Priyanka Gupta, David Hayes, Maria Myzithras and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 185 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. GDF11-secreting cell transplant efficiently ameliorates age-related pulmonary fibrosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. GDF11 and aging biology - controversies resolved and pending.The journal of cardiovascular aging · 2023
    Article
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Shavonn C SmithFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Xiaoxiao ZhangFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Xiaoying ZhangFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Polina GrossFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Timothy StarostaFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Sadia MohsinFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Michael FrantiFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Priyanka GuptaFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
David HayesFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Maria MyzithrasFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Julius KahnFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
James TannerFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Steven M WeldonFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Ashraf KhalilFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Xinji GuoFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Abdelkarim SabriFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Xiongwen ChenFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Scott MacDonnellFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell).
Steven R HouserFrom the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA (S.C.S., Xiaoxiao Zhang, Xiaoying Zhang, P.G., T.S., S Mohsin, X.G., A.S., X.C., S.R.H.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (M.F., P.G., D.H., M.M., J.K., J.T., S.M.W., A.K., S. MacDonnell). srhouser@temple.edu.
Boehringer Ingelheim (France) · FR

Funding

Targeted Cancer Therapeutics and Heart Failure: Mechanisms and Post-injury RepairP01HL091799 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI HOUSER, STEVEN R · 2008 to 2018
$23.1M
PKC alpha as a translational target in Heart FailureP01HL108806 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI RABINOWITZ, JOSEPH E · 2012 to 2016
$11.3M
Calcium and Cardiac Regeneration after Myocardial InfarctionR01HL033921 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI HOUSER, STEVEN R · 1985 to 2017
$5.6M
Integrative Cardiovascular PathophysiologyT32HL091804 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI ELROD, JOHN WILLIAM · 2008 to 2024
$4.5M
Protein Kinase A Inhibitor Peptide (PKI) and Cardiac Protection in Heart FailureR01HL088243 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CHEN, XIONGWEN · 2007 to 2017
$4.0M
Inflammatory serine proteases and cardiac repair post myocardial infarctionR01HL128446 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI SABRI, ABDELKARIM · 2015 to 2018
$1.6M
NHLBI NIH HHS P01 HL091799NHLBI NIH HHS P01 HL108806NHLBI NIH HHS R01 HL033921NHLBI NIH HHS R01 HL088243NHLBI NIH HHS R01 HL128446NHLBI NIH HHS T32 HL091804
6 · The paper itself

Abstract

rationaleGrowth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β super family of secreted factors. A recent study showed that reduced GDF11 blood levels with aging was associated with pathological cardiac hypertrophy (PCH) and restoring GDF11 to normal levels in old mice rescued PCH.

objectiveTo determine whether and by what mechanism GDF11 rescues aging dependent PCH. METHODS AND

resultsTwenty-four-month-old C57BL/6 mice were given a daily injection of either recombinant (r) GDF11 at 0.1 mg/kg or vehicle for 28 days. rGDF11 bioactivity was confirmed in vitro. After treatment, rGDF11 levels were significantly increased, but there was no significant effect on either heart weight or body weight. Heart weight/body weight ratios of old mice were not different from 8- or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young versus old mice. Ejection fraction, internal ventricular dimension, and septal wall thickness were not significantly different between rGDF11 and vehicle-treated animals at baseline and remained unchanged at 1, 2, and 4 weeks of treatment. There was no difference in myocyte cross-sectional area rGDF11 versus vehicle-treated old animals. In vitro studies using phenylephrine-treated neonatal rat ventricular myocytes, to explore the putative antihypertrophic effects of GDF11, showed that GDF11 did not reduce neonatal rat ventricular myocytes hypertrophy, but instead induced hypertrophy.

conclusionsOur studies show that there is no age-related PCH in disease-free 24-month-old C57BL/6 mice and that restoring GDF11 in old mice has no effect on cardiac structure or function.

Indexed as

Adrenergic alpha-1 Receptor AgonistsAge FactorsAgingAnimalsBone Morphogenetic ProteinsCardiomegalyCells, CulturedDrug Administration ScheduleFibroblastsFibrosisGrowth Differentiation FactorsInjections, IntraperitonealMaleMice, Inbred C57BLMyocytes, CardiacRecombinant ProteinsAdrenergic alpha-1 Receptor AgonistsBone Morphogenetic ProteinsGDF11 protein, humanGrowth Differentiation FactorsRecombinant Proteinsagingbody weightcardiac function testsgrowth differentiation factorstransforming growth factor beta

Identifiers

PMID26383970
PMCPMC4636963
OpenAlexW2100317831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.